Trial
NCT03459443
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
C3 Glomerulonephritis
Intervention
Danicopan
Why stopped
The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-21